Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
S Kor Spoelstra, Jojanneke Bruins, Leonie Bais, Paul Seerden, Stynke Castelein & Henderikus Knegtering. (2022) One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives. Patient Preference and Adherence 16, pages 615-624.
Read now
Read now
Francesco Pietrini, Umberto Albert, Andrea Ballerini, Paola Calò, Giuseppe Maina, Federica Pinna, Marco Vaggi, Ileana Boggian, Maria Fontana, Cesare Moro & Bernardo Carpiniello. (2019) The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1045-1060.
Read now
Read now
Maju Mathews, Isaac Nuamah, Adam J Savitz, David W Hough, Dean Najarian, Edward Kim & Srihari Gopal. (2018) Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. Neuropsychiatric Disease and Treatment 14, pages 2807-2816.
Read now
Read now
Robin Emsley & Sanja Kilian. (2018) Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Disease and Treatment 14, pages 205-223.
Read now
Read now
Adam J Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Paulien Ravenstijn, David Hough, Maju Mathews, Yu Feng, Lu Yu, Masayoshi Takahashi, Dennis Liu, Gang Wang, Jin-Sang Yoon & Jiahn-Jyh Chen. (2017) Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. Neuropsychiatric Disease and Treatment 13, pages 2193-2207.
Read now
Read now
Articles from other publishers (3)
L.A. Burygina, S.A. Golubev, A.Yu. Berezantsev & E.A. Shumakova. (2022) Transfer from paliperidone of one-month action to paliperidone of three-month action in schizophrenia spectrum disorders: clinical aspects, pharmacological strategies, therapeutic prediction. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122:1, pages 13.
Crossref
Crossref
Adam J. Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews & Bernardo Soares. (2019) Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies. Brazilian Journal of Psychiatry 41:6, pages 499-510.
Crossref
Crossref
Nagesh Pai & Matthew Warden. (2018) Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate. Australasian Psychiatry 26:6, pages 628-634.
Crossref
Crossref